Table 1 Patient baseline characteristics.
Recipient | Transplantation | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Gender | Age at nephrectomy (y) | Cause of ESRD | Number of previous renal transplants | Donor type | CMV status donor* | CMV status acceptor* | Maintenance IS | Anti-rejection treatment | Time to explantation (days) | Cause of graft failure | |
1. | M | 30 | Hypertensive nephropathy | 0 | L | − | + | Tac, MMF, Pred | MP, IvIg, plasmaferese, Alemtuzumab | 8 | aTCMR2B and aABMR and pyelonephritis |
2. | F | 48 | ADPKD | 0 | L | − | + | Bela, Tac**, MMF, Pred, Basiliximab | MP, Alemtuzumab | 12 | aTCMR2B and aABMR |
3. | M | 63 | Hypertension nephropathy | 0 | D | + | + | Tac, MMF, Pred, Basiliximab | MP, IVIg | 15 | aTCMR 2B and aABMR |
4. | F | 28 | GPA | 1 | L | + | − | Tac, MMF, Pred | IVIg, Alemtuzumab | 150 | aTCMR3 and aABMR |
5. | M | 46 | ADPKD | 0 | L | + | − | Tac, MMF, Pred | MP | 270 | aTCMR3 |
6. | F | 67 | Hypertension nephropathy | 0 | D | − | + | None# | MP | 390 | aTCMR3 and aABMR |
7. | M | 71 | Diabetic nephropathy | 1 | D | + | + | Tac, MMF | MP | 2268 | aTCMR3 and c-aABMR |
8. | M | 29 | HUS | 0 | D | − | − | Tac, MMF | None | 2340 | c-aABMR |
9. | M | 24 | FSGS | 0 | L | + | + | MMF, Pred, Ecu*** | MP, IVIg | 2520 | c-aABMR |
10. | M | 51 | Congenital hydronephrosis | 0 | D | − | − | Tac | None | 3240 | aTCMR2B and aABMR |
11. | F | 51 | poststreptococcal glomerulo- nephritis | 0 | D | + | − | None# | None | 3780 | c-aABMR and c-aTCMR |
12. | M | 53 | Hypertension nephropathy | 1 | L | + | + | Tac, Pred | None | 4320 | aTCMR3 |
13. | M | 57 | Hypertension nephropathy | 0 | D | + | + | Aza, Pred | None | 9360 | End-stage kidney |
